海昇药业
(920656)
| 流通市值：11.93亿 | | | 总市值：14.61亿 |
| 流通股本：8162.86万 | | | 总股本：1.00亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 141,142,471.8 | 65,642,203.39 | 220,598,316.5 | 163,844,572.3 |
| 营业收入 | 141,142,471.8 | 65,642,203.39 | 220,598,316.5 | 163,844,572.3 |
| 二、营业总成本 | 90,517,235.86 | 44,276,393.9 | 149,016,474.19 | 111,159,132.03 |
| 营业成本 | 76,629,442.94 | 36,954,558.56 | 126,003,200.09 | 93,883,386.01 |
| 税金及附加 | 2,050,028.56 | 520,252.07 | 1,865,460.45 | 1,468,365.69 |
| 销售费用 | 1,879,484.55 | 1,636,967.64 | 2,635,586.54 | 2,202,949.44 |
| 管理费用 | 3,980,530.19 | 2,173,614.54 | 8,618,459.93 | 6,500,455.08 |
| 研发费用 | 5,097,662.1 | 2,747,108.04 | 10,529,197.62 | 7,781,621.25 |
| 财务费用 | 880,087.52 | 243,893.05 | -635,430.44 | -677,645.44 |
| 其中:利息收入 | 1,030,772.66 | 513,649.22 | 1,346,462.58 | 901,144.16 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | - | 216,333 | - |
| 加:投资收益 | 3,450,535.06 | 1,845,792.75 | 6,984,077.42 | 3,111,195.97 |
| 资产减值损失(新) | 18,487.22 | -77,115.85 | -472,839.65 | 51,960.12 |
| 信用减值损失(新) | -168,053.92 | -372,465.11 | -462,152.11 | -963,996.93 |
| 其他收益 | 684,224.56 | 456,483.46 | 2,322,669.21 | 1,778,034.29 |
| 四、营业利润 | 54,610,428.86 | 23,218,504.74 | 80,169,930.18 | 56,662,633.72 |
| 加:营业外收入 | 35,028 | - | 19,800 | 19,800 |
| 减:营业外支出 | 100,250 | - | 1,228.74 | 1,228.74 |
| 五、利润总额 | 54,545,206.86 | 23,218,504.74 | 80,188,501.44 | 56,681,204.98 |
| 减:所得税费用 | 7,524,099.44 | 3,126,024.78 | 10,731,517.92 | 7,633,848.28 |
| 六、净利润 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| 扣除非经常损益后的净利润 | 44,158,628.82 | 18,523,556.12 | 62,534,517.09 | 45,665,410.84 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.47 | 0.2 | 0.69 | 0.49 |
| (二)稀释每股收益 | 0.47 | 0.2 | 0.69 | 0.49 |
| 九、综合收益总额 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| 归属于母公司股东的综合收益总额 | 47,021,107.42 | 20,092,479.96 | 69,456,983.52 | 49,047,356.7 |
| 公告日期 | 2026-08-20 | 2026-04-16 | 2026-04-16 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |